Literature DB >> 15527679

Medical therapy for ulcerative colitis: the state of the art and beyond.

Andrew S Ross1, Russell D Cohen.   

Abstract

Ulcerative colitis (UC) is an idiopathic inflammatory condition of the large intestine. Recent advances in our understanding of the pathogenesis of UC have led to the development of novel treatments for this often debilitating condition. Aside from aminosalicylates and corticosteroids, drugs that have been used for decades in the treatment of UC, biologic agents, in addition to medications targeting specific effector mechanisms involved in the inflammatory cascade, have been used in patients with UC with varying degrees of success. Clinicians have never had as many therapeutic options for UC as they do today. Herein we review the variety of treatment options, both standard and investigational, that are available for patients with UC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15527679     DOI: 10.1007/s11894-004-0071-9

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  43 in total

1.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

Review 2.  The state of the art in the management of inflammatory bowel disease.

Authors:  Stephen B Hanauer; Daniel H Present
Journal:  Rev Gastroenterol Disord       Date:  2003

3.  Infliximab for treatment of steroid-refractory ulcerative colitis.

Authors:  G C Actis; M Bruno; M Pinna-Pintor; F P Rossini; M Rizzetto
Journal:  Dig Liver Dis       Date:  2002-09       Impact factor: 4.088

4.  Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.

Authors:  I Dotan; A Hallak; N Arber; M Santo; A Alexandrowitz; Y Knaani; R Hershkoviz; E Brazowski; Z Halpern
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

5.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Authors:  Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

Review 6.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors:  L Sutherland; J K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2003

7.  Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.

Authors:  W J Sandborn; B E Sands; D C Wolf; J F Valentine; M Safdi; S Katz; K L Isaacs; L D Wruble; J Katz; D H Present; E V Loftus; F Graeme-Cook; D J Odenheimer; S B Hanauer
Journal:  Aliment Pharmacol Ther       Date:  2003-06-01       Impact factor: 8.171

8.  The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.

Authors:  Wolfgang Kruis; Simon Bar-Meir; Janos Feher; Oliver Mickisch; Horst Mlitz; Marek Faszczyk; Yehuda Chowers; Gabriella Lengyele; Agotá Kovacs; László Lakatos; Manfred Stolte; Michael Vieth; Roland Greinwald
Journal:  Clin Gastroenterol Hepatol       Date:  2003-01       Impact factor: 11.382

9.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Authors:  C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

10.  Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis.

Authors:  Joris Arts; Geert D'Haens; Miranda Zeegers; Gert Van Assche; Martin Hiele; André D'Hoore; Freddy Penninckx; Severine Vermeire; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-03       Impact factor: 5.325

View more
  8 in total

1.  Disrupted pancreatic exocrine differentiation and malabsorption in response to chronic elevated systemic glucocorticoid.

Authors:  Karen Wallace; Paul A Flecknell; Alastair D Burt; Matthew C Wright
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

2.  A Comprehensive Review of Topical Therapies for Distal Ulcerative Colitis.

Authors:  Russell D Cohen; Roni Weisshof
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-01

3.  Procyanidin A1 alleviates DSS-induced ulcerative colitis via regulating AMPK/mTOR/p70S6K-mediated autophagy.

Authors:  Haihua Zhang; Wuying Lang; Xin Liu; Jiangsong Bai; Qinghui Jia; Qiumei Shi
Journal:  J Physiol Biochem       Date:  2022-01-10       Impact factor: 4.158

4.  Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.

Authors:  Kunwar Shailubhai; Vaseem Palejwala; Krishna Priya Arjunan; Sayali Saykhedkar; Bradley Nefsky; John A Foss; Stephen Comiskey; Gary S Jacob; Scott E Plevy
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

5.  Diagnostic and Clinical Significance of Serum Levels of D-Lactate and Diamine Oxidase in Patients with Crohn's Disease.

Authors:  Jierui Cai; Hong Chen; Meiling Weng; Shuyu Jiang; Jie Gao
Journal:  Gastroenterol Res Pract       Date:  2019-08-19       Impact factor: 2.260

6.  Anti-Inflammatory Effects of Huangqin Decoction on Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice Through Regulation of the Gut Microbiota and Suppression of the Ras-PI3K-Akt-HIF-1α and NF-κB Pathways.

Authors:  Min-Yao Li; Hui-Juan Luo; Xue Wu; Yu-Hong Liu; Yu-Xuan Gan; Nan Xu; Yao-Min Zhang; Shu-Hua Zhang; Chang-Lin Zhou; Zi-Ren Su; Xiao-Qi Huang; Xue-Bao Zheng
Journal:  Front Pharmacol       Date:  2020-01-20       Impact factor: 5.810

7.  Comparative Evaluation between Sulfasalazine Alone and in Combination with Herbal Medicine on DSS-Induced Ulcerative Colitis Mice.

Authors:  Mi-Rae Shin; Kyeong Jo Kim; Soo Hyun Kim; Su Ji Kim; Bu-Il Seo; Hyo-Jin An; Seong-Soo Roh
Journal:  Biomed Res Int       Date:  2017-09-06       Impact factor: 3.411

8.  New approach of medicinal herbs and sulfasalazine mixture on ulcerative colitis induced by dextran sodium sulfate.

Authors:  Mi-Rae Shin; Hae-Jin Park; Bu-Il Seo; Seong-Soo Roh
Journal:  World J Gastroenterol       Date:  2020-09-21       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.